Align Technology Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Jefferies Global Healthcare Conference in London. My name's Mike Sarcone. I'm an analyst on the U.S. Medical Supplies and Devices team at Jefferies, and this is a session for Align Technology. Up on the dais with us, we have Joe Hogan, CEO, and John Morici, CFO. Also joined in the room is Jennifer Davis, incoming CEO, and Shirley Stacy, Head of IR. Thank you very much for joining us today, gentlemen.
Of course. Thank you. Thanks, Mike.
I guess just to kick off, Joe, a few weeks ago in conjunction with 3Q results that you reported, you announced your planned succession and retirement. Maybe we were hoping you could comment on the timing and the announcement, and then just give us your thoughts on the positioning of the company as you hand over the reins.
Yeah, sure. I've been with ABB for 11 years now. I'm sorry, ABB. I left ABB to join Align 11 years ago. 11 years, I think, is long enough. I'm approaching 69 years old. I'm approaching 70 years old in May next year, and I think it was time for me to stand back from the business and also take another look at life. We've had a really good process internally in the sense of looking at candidates over a year and a half period. Jennifer turned out just a terrific candidate for the job, and I couldn't be more excited about turning over the role to Jennifer. She has a terrific background for us from her P&G time together. We've been beginning this transition over the last couple months, and we'll finish it through December.
I feel really good about the status of the business and Jen's ability to take it over.
Okay, great. Well, we wish you the best. It's been great working with you, and we're looking forward to working with Jennifer as well. I guess maybe, shifting gears, touch on the macro a bit. On the 3Q call a few weeks ago, you mentioned or you characterized discretionary dental and ortho demand as challenged. Maybe you can elaborate more on what you're seeing and how it varies across region and channel.
Yeah. I'd say nothing really changed in the third quarter from what we talked about before. Obviously, consumer demand is a big variable in our equation overall, and we know consumers are challenged. Our business is mostly out-of-pocket costs in that sense. But overall, we felt good about our performance in third quarter across the globe in different areas. Obviously, some products that we've announced recently, which are more, I think, viable from a consumer standpoint in lowering prices, like the Zero AA product was a big help. You had a real dichotomy between Invisalign sales, which did fairly well, versus iTero, which obviously year-on-year was down. But we did sell more units from an iTero standpoint, which lays a really good foundation for the business overall for growth in the future, because we know more iTero placements will work.
Overall, no surprises in the third quarter.
Okay. I thought the team executed well.
John, you have anything to add?
No. I mean, it is a similar environment that we have seen for a number of quarters now. As Joe said, we want to do things in a tough environment to help with our doctors, lower some of the upfront costs, and some of our technology and products are able to do that with the Zero AA or even going a ways back, the three and three, which was moving from the comprehensive unlimited to help with lowering the upfront cost, and then also helping with patient financing. Doing a lot of things to try to connect that patient who might be reluctant to go into treatment. If there are things that we can do to get them into treatment with the financing and so on, we think that helps differentiate, and that is something that we have had to do for several quarters, and we are seeing good momentum around those two aspects.
Okay. That makes sense. I guess, we are midway through calendar 4Q. Have you seen kind of relative stability versus what you saw in 3Q, and any changes to note, I guess, as it relates to the macro?
When we made our forecast for 4Q, it was based on we were already through the month of October, so our forecast pretty much reflects what we've seen between the two quarters.
Okay. On the aligner side, you lowered your 2026 sales guide primarily due to the scanner revenues. You just mentioned that. It also included, we can call it a modest moderation in your outlook for aligner growth. I think it implies maybe aligner sales decelerate to about a low single-digit pace in 4Q. I guess, can you just speak to kind of guidance construction and, I guess, what was incorporated in there?
Yeah. As Joe said, we wanted to be able to include what we saw as we went through third quarter, what we saw starting fourth quarter, be prudent about our guidance so that we could reflect what the demand looks like, not just in North America, but across the globe. That was a reflection of that. As you said, the majority of adjustment was really due to iTero. It's just not for a lack of volume. The units have been great.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
